Rambam Health Care Campus
Haifa, 210961, Israel
Location status: Recruiting
NCT Number: NCT07368322
Abstract Background: Aortic valve replacement (AVR) is crucial for patients with severe aortic valve disease. However, managing those with a small aortic annulus (SAA, i.e., annulus diameter < 22 mm) is challenging because implanting a small prosthesis can result in patient-prosthesis mismatch (PPM), suboptimal hemodynamic outcomes, and reduced long-term survival. Traditional surgical techniques for aortic root enlargement (ARE), such as the Nicks and Manougian procedures, have significant limitations, typically allowing enlargement of only one to two prosthesis sizes and involving complex reconstructive procedures. The novel "Y incision" technique by Bo Yang offers a promising alternative, allowing implantation of valves up to five sizes larger than the native annulus, but it lacks comprehensive comparative data on its safety, efficacy, and functional outcomes.
Aim: This study aims to compare the safety outcomes, hemodynamic performance, and functional capacity of the "Y incision" technique versus standard surgical enlargement techniques in patients with a small aortic annulus undergoing AVR, with particular emphasis on objective functional assessment using cardiopulmonary exercise testing (CPET).
Methods: This prospective, randomized, controlled superiority trial will enroll patients with aortic valve disease and a small aortic annulus where conventional AVR is expected to result in moderate or severe PPM. Patients will be randomized 1:1 to either the standard surgical technique group or the "Y incision" technique group. Based on preliminary results and power calculations using the Win Ratio methodology, the sample size is set at 90 patients (45 in each group) to account for potential dropouts.
Primary Endpoint: Hierarchical composite endpoint analyzed using Win Ratio methodology, including (in order of priority): all-cause mortality, stroke, myocardial infarction, total hospitalization rate, moderate or severe PPM, exercise-induced valve dysfunction, and functional improvement at specified time points through 12 months.
Secondary Endpoints: Safety outcomes including intraoperative and 30-day complications, long-term anatomical complications, hemodynamic parameters assessed by echocardiography, functional outcomes measured by 6-minute walk distance and CPET (including peak VO₂), quality of life assessed using KCCQ questionnaire, and prosthetic valve-related outcomes at 3, 6, and 12 months post-surgery.
Conclusion: By providing robust, randomized controlled data with objective functional capacity assessment, this study aims to fill current gaps in knowledge regarding the long-term outcomes, safety profile, and functional benefits of the "Y incision" technique compared to standard surgical methods, potentially establishing evidence-based guidance for managing patients with a small aortic annulus undergoing AVR.
Interested in participating?
Request Info18 year–80 year
All sexes
Interventional
Not applicable
Haifa, 210961, Israel
Location status: Recruiting
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
A "Y"-shaped incision is made from the aortotomy, extending through the left coronary-noncoronary commissure into the aortomitral curtain. Thereafter, a Hemashield patch is sewn to the aortomitral curtain and the undermined aortic annulus, creating a larger space, and the bioprosthetic valve is placed and secured. Finally, the modified aortotomy is closed using the roof technique for better hemostasis and to enlarge the sinotubular junction and proximal ascending aorta. This technique allows the implantation of a valve up to five sizes larger than the native annulus.
Traditional approaches include aortic root enlargement procedures such as the Nicks, Manougian, and Konno techniques; these procedures aim to widen the annulus and accommodate a larger prosthetic valve, thereby reducing the risk of PPM.
Time frame: At specified time points through 12 months
A composite hierarchical endpoint analyzed using the Win Ratio methodology. Pairs of patients (one from each study arm) are compared based on a prioritized sequence of outcomes. The hierarchy is: 1. Time to all-cause mortality; 2. Incidence of stroke; 3. Incidence of myocardial infarction; 4. Frequency of total hospitalizations; 5. Presence of moderate/severe Prosthesis-Patient Mismatch (PPM); 6. Exercise-induced valve dysfunction; and 7. Improvement in functional status (defined as ≥1 NYHA class improvement). A "win" is assigned to the patient with the better outcome at each step.
Win Ratio - The ratio of the total number of wins in the intervention group to the total number of wins in the control group.
Time frame: Up to 12 months.
Number of participants experiencing intraoperative and 30-day complications, and long-term anatomical complications (including valve thrombosis or migration).
Unit of Measure: Number of participants.
Time frame: Baseline, 3, 6, and 12 months.
Assessment of the prosthetic valve mean pressure gradient as measured by transthoracic echocardiography.
Unit of Measure: mmHg.
Time frame: Baseline and 12 months.
Change from baseline in the distance walked during a 6-minute period. Unit of Measure: Meters.
Time frame: Baseline, 3, 6, and 12 months.
Change in the Kansas City Cardiomyopathy Questionnaire (KCCQ-12) overall summary score. Scores range from 0 to 100, where higher scores represent better health status.
Unit of Measure: Points on a scale.
Time frame: Baseline and 12 months post-surgery.
Peak VO2 attained during Cardiopulmonary Exercise Testing (CPET) using a standardized ramp protocol on a cycle ergometer or treadmill. Unit of Measure: mL/kg/min
Time frame: 3, 6, and 12 months post-surgery.
Number of participants experiencing specific valve-related adverse events, including prosthetic valve thrombosis, device migration, endocarditis, or structural valve deterioration (SVD) as defined by VARC-3 criteria.
Unit of Measure: Number of participants
Time frame: Within 30 days post-surgery.
A composite of safety events occurring within the early postoperative period, including major bleeding (BARC type 3 or 5), acute kidney injury (Stage 2 or 3), and new-onset permanent atrial fibrillation.
Unit of Measure: Number of participants
Time frame: Baseline, 3, 6, and 12 months post-surgery.
The Effective Orifice Area of the prosthetic valve calculated via the continuity equation using transthoracic echocardiography (TTE) measurements. Unit of Measure: cm^2
Time frame: Baseline, 3, 6, and 12 months post-surgery.
Assessment of heart failure symptoms according to the New York Heart Association (NYHA) Functional Classification. Scores range from Class I (no symptoms) to Class IV (severe symptoms).
Unit of Measure: NYHA Class (I, II, III, or IV)
Contact information is provided by the study sponsor or research team.
willner nadav MD
Other
Comparative Analysis of Standard Surgical Techniques vs. "Y Incision" Technique for Aortic Root Enlargement in Patients With Small Aortic Annulus Undergoing Aortic Valve Replacement: A Randomized Open-Label Controlled Trial (CRYSTAL Trial - Comparative Research of Y-Incision vs. Standard Techniques for Aortic Root EnLargement)
Acronym: CRYSTAL
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04696926
Aortic Valve Disease, Aortic Valve Insufficiency
Marseille, France
View Trial DetailsNCT02744677
Aortic Valve Disease, Aortopulmonary Septal Defect
Birmingham, Alabama, United States
View Trial DetailsNCT07619872
Aortic Valve Disease, Cardiovascular Diseases
München, Bavaria, Germany
View Trial DetailsNCT04258488
AORTIC VALVE DISEASES, Aortic Valve Disease
Bucheon-si, South Korea
View Trial Details